Nano-Strategies for Improving the Bioavailability of Inhaled Pharmaceutical Formulations

Author:

Xing Yue1,Lu Peng1,Xue Zhifeng1,Liang Chunxia1,Zhang Bing1,Kebebe Dereje1,Liu Hongfei2,Liu Zhidong1

Affiliation:

1. Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

2. College of Pharmacy, Jiangsu University, Zhenjiang 212013, China

Abstract

Pulmonary pharmaceutical formulations are targeted for the treatment of respiratory diseases. However, their application is limited due to the physiological characteristics of the lungs, such as branching structure, mucociliary and macrophages, as well as certain properties of the drugs like particle size and solubility. Nano-formulations can ameliorate particle sizes and improve drug solubility to enhance bioavailability in the lungs. The nano-formulations for lungs reviewed in this article can be classified into nanocarriers, no-carrier-added nanosuspensions and polymer-drug conjugates. Compared with conventional inhalation preparations, these novel pulmonary pharmaceutical formulations have their own advantages, such as increasing drug solubility for better absorption and less inflammatory reaction caused by the aggregation of insoluble drugs; prolonging pulmonary retention time and reducing drug clearance; improving the patient compliance by avoiding multiple repeated administrations. This review will provide the reader with some background information for pulmonary drug delivery and give an overview of the existing literature about nano-formulations for pulmonary application to explore nano-strategies for improving the bioavailability of pulmonary pharmaceutical formulations.

Funder

Scientific Research Project of Tianjin Municipal Education Commission

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology,General Medicine

Reference181 articles.

1. Conti,S.; Harari,S.; Caminati,A.; Zanobetti,A.; Schwartz, J.D.; Bertazzi, P.A.; Cesana,G.; Madotto, F. The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy. Eur. Respir, J. 2018,51(1),1700397. http://dx.doi.org/10.1183/13993003.00397-2017 PMID: 29371377

2. Shin, I.S.; Shin, N.R.; Park, J.W.; Jeon, C.M.; Hong, J.M.; Kwon, O.K.; Kim, J.S.; Lee, I.C.; Kim, J.C.; Oh, S.R.; Ahn, K.S. Melato-nin attenuates neutrophil inflammation and mucus secretion in ci-garette smoke-induced chronic obstructive pulmonary diseases via the suppression of Erk-Sp1 signaling, J. Pineal Res. 2015,58(1),50-60. http://dx.doi.org/10.1111/jpi.12192 PMID: 25388990

3. Haktanir Abul,M.; Phipatanakul, W. Severe asthma in children: Evaluation and management. Allergol. Int. 2019,68(2),150-157. http://dx.doi.org/10.1016/j.alit.2018.11.007 PMID: 30648539

4. Osuoha, C.A.; Callahan, K.E.; Ponce, C.P.; Pinheiro, P.S. Dispari-ties in lung cancer survival and receipt of surgical treatment. Lung Cancer. 2018,122,54-59. http://dx.doi.org/10.1016/j.lungcan.2018.05.022 PMID: 30032845

5. Abdelaziz, H.M.; Gaber,M.; Abd-Elwakil, M.M.; Mabrouk, M.T.; Elgohary, M.M.; Kamel, N.M.; Kabary, D.M.; Freag, M.S.; Sa-maha, M.W.; Mortada, S.M.; Elkhodairy, K.A.; Fang, J.Y.; Elzo-ghby, A.O. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates, J. Control. Release. 2018,269,374-392. http://dx.doi.org/10.1016/j.jconrel.2017.11.036 PMID: 29180168

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3